Hanmi Pharmaceutical on Oct. 27 posted in its preliminary earnings an operating profit of 37.8 billion won ($28.5 million) for the quarter ended September, down 31.3 percent from a year earlier and below the market consensus of 39.9 billion won. Revenue rose 4.2 percent to 377.4 billion won, while net profit fell 69.1 percent to 14 billion won.
Revenue at its Chinese unit, Beijing Hanmi Pharmaceutical, fell 15.8 percent to 79.3 billion won, while Hanmi’s standalone operating profit rose 9.7 percent. Operating profit also dropped from 131.1 billion won in the second quarter, which included a one-time upfront payment for licensing out the drug candidate sonefpeglutide.
Copyright ⓒ Aju Press All rights reserved.
